Vass CM, Boeri M, Poulos C, Turner AJ. Matching and weighting in stated preferences for health care. Journal of choice modelling. 2022 Sep;44. doi: 10.1016/j.jocm.2022.100367
Loria LE, Watson V, Kiso T, Phimister E. Investigating users' preferences for low emission buses: experiences from Europe's largest hydrogen bus fleet. Journal of choice modelling. 2019 Sep;32:100169. doi: 10.1016/j.jocm.2019.05.001
Pujol J, Martinez-Vilavella G, Macia D, Fenoll R, Alvarez-Pedrerol M, Rivas I, Forns J, Blanco-Hinojo L, Capellades J, Querol X, Deus J, Sunyer J. Traffic pollution exposure is associated with altered brain connectivity in school children. Neuroimage. 2016 Apr;1(129):175-84. doi: 10.1016/j.neuroimage.2016.01.036.
Park EM, Deal AM, Yopp JM, Edwards T, Stephenson EM, Hailey CE, Nakamura ZM, Rosenstein DL. End-of-life parental communication priorities among bereaved fathers due to cancer. Patient Educ Couns. 2015 May;100(5):1019-23. doi: 10.1016/j.pec.2016.12.007
Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20.
Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.
Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.
Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.